BioSpace News Archive

Voyager Therapeutics, Inc. today announced that CEO Alfred W. Sandrock, Jr., M.D., Ph.D., will present at the upcoming 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023, at 10:30 a.m. PT / 1:30 p.m. ET.

Aravive, Inc. today announced the achievement of full enrollment in the registrational Phase 3 trial of batiraxcept plus paclitaxel for platinum-resistant ovarian cancer (PROC).

Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today outlined its recent accomplishments and expected 2023 milestones.

Coherus BioSciences, Inc., announced that senior management will present at the upcoming 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 8:15 a.m. Pacific Time.

HOOKIPA Pharma Inc., a company developing a new class of immunotherapies based on its proprietary arenavirus platform, announced that it has achieved a $5 million non-dilutive milestone payment under its collaboration agreement with Gilead Sciences, Inc.

Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX) today announced that its research collaborators at the University of Pittsburgh will present preclinical data highlighting the therapeutic potential of Genprex’s gene therapy for Type 1 diabetes at the 16th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2023) being held February 22-25 in Berlin, Germany and online.

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) today announced that the Company’s senior management team will participate at the 41st Annual J.P. Morgan Healthcare Conference in a podium presentation on Wednesday, January 11 at 10:30 a.m. PT, followed by a question-and-answer breakout session at 10:50 a.m. PT.

Hemogenyx Pharmaceuticals plc, the biopharmaceutical group developing new therapies and treatments for deadly blood diseases, is pleased to announce the successful completion of its second Process Qualification run of the end-to-end process for the manufacture of HEMO-CAR-T cells.

Sihuan Pharmaceutical Holdings Group Co., Ltd. is pleased to announce that the Group’s Jilin Huisheng Biopharmaceutical Co., Ltd., a non-wholly owned subsidiary, has successfully completed the acquisition of Jilin Baixing Bairong Investment Center *, JiLin Province Private Equity Co., Ltd., Jilin Province Technology Investment Fund Co., Ltd. in the A+ round of financing by way of capital increase.

Pharnext SA, an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases with high unmet medical need, announces the appointment of Scott Johnson as VP, Head of Quality.